HPV Vaccine Ceravix Protects Against Cancer In Just One Dose, New Study Reveals

A major new study has found that a single dose of the human papillomavirus vaccine, Cervarix, is just as effective as the currently recommended three doses when it comes to protecting against two high risk, cancer-causing strains of the virus.

What’s more, a special two-shot protocol could protect against additional strains of the virus not previously thought to be addressed by the vaccine.

The Background

Cervical cancer is the fourth most common cancer for women across the globe, and by 2020, it’s estimated that oropharyngeal cancer — which is found in the back of the throat and affects both men and women — will be the most common HPV-related cancer in the world.

A vaccine for these diseases is available in the form of the HPV vaccine, but not very many people are getting it. While you might think that people would be lined up around the block to get shots that can prevent genital warts as well as cancer in the cervix, anus, vagina, penis and the back of the throat, the rates of vaccination in the U.S. have been disappointingly low ever since the vaccine debuted in 2006.

The Setup

For this new study, researchers behind two large landmark HPV vaccine trials got together to combine the data on a total of 26,110 female participants who had been randomized to receive either three shots of the HPV vaccine Cervarix, which was approved for girls and women in 2009, or control injections.

For a number of life reasons, like pregnancy, some women stopped at just one or two HPV vaccine shots and couldn’t complete the series of three. Investigators like Dr. Cosette Wheeler, who studies HPV at the University of New Mexico Health Sciences Center, wanted to look back at the data after the trial was done —> Read More